STUDY SPOTLIGHT: Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia
This multi-center open label clinical trial aims to identify predictors of low antibody titers to vaccine antigens in children with ALL who completed chemotherapy in the prior 6 months, and to determine the immunogenicity and safety of diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-Hib) and 13-valent pneumococcal conjugate vaccine (PCV13) booster immunization administered 6 months post-chemotherapy, followed by 23-valent pneumococcal polysaccharide vaccination (PPV23) 2 months later. The results will support the development of clinical practice guidelines for this population.
Official Title: Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study
Cooperative Group: Canadian Immunization Research Network (CIRN)
Study ID: NCT02447718, CIRN SI02
For more information see, https://clinicaltrials.gov/ct2/show/NCT02447718 and http://cirnetwork.ca/research-study/vaccinating-after-chemotherapy-or-hematopoietic-stem-cell-transplant/